Asad Haider
Stock Analyst at Goldman Sachs
(2.42)
# 2,278
Out of 4,826 analysts
5
Total ratings
100%
Success rate
8.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $155.01 | +10.96% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $821.58 | +8.08% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $195.65 | -0.84% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $49.82 | +10.40% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $23.97 | +4.30% | 1 | Apr 8, 2025 |
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $155.01
Upside: +10.96%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $821.58
Upside: +8.08%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $195.65
Upside: -0.84%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $49.82
Upside: +10.40%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $23.97
Upside: +4.30%